Between FY18-20 Chemcon's revenues have grown at CAGR of 29% while PAT grew at higher rate of 36% CAGR. The management believes the company can grow at 15-18% CAGR for next 2-3 years. EBITDA/ton is expected to remain steady although volumes are likely to improve on the back of (a) strong demand outlook (b) expanded capacity. The issue price commands P/E of 25.5x (FY20) at the upper price of band of Rs 338-340, which is well within the industry range. We recommend Subscribe on the issue for listing gains.

10 each, (Comprising of fresh issue of 4,852,941 Equity Shares* (Rs. 165 cr.) and Offer for Sale of 4,500,000 Equity Shares* (Rs. 318 cr.) by Selling Shareholder)....

Incorporated on December 15, 1988, Chemcon Speciality Chemicals Ltd (Chemcon) is a manufacturer of specialised chemicals, such as Hexamethyldisilazane / Hexamethyldisilane (HMDS) and Chloromethyl Isopropyl Carbonate (CMIC) which are predominantly used in the pharmaceuticals industry (Pharmaceutical Chemicals), and inorganic bromides, namely Calcium Bromide, Zinc Bromide and Sodium Bromide, which are predominantly used as completion...